Table 4 Summary of maternal and foetal SARS-CoV-2 genome (a) and anti-SARS-CoV-2 antibody (b) detection.
From: Analysis of SARS-CoV-2 vertical transmission during pregnancy
(a) | Maternal plasma (n = 30) | Vaginal swab (n = 31) | Placenta (n = 31) | Umbilical cord plasma (n = 30) | Umbilical cord (n = 12) | Amniotic fluid (n = 6) | Milk (n = 11) |
|---|---|---|---|---|---|---|---|
Pos, % (n) | 6.7 (2) | 3.2 (1) | 6.4 (2) | 3.3 (1) | 0 (0) | 0 (0) | 9.1 (1) |
(b) | Maternal plasma (n = 30) | Umbilical cord plasma (n = 30) | Milk (n = 10) |
|---|---|---|---|
IgM, % (n) | 32.1 (9) | 3.3 (1) | 10 (1) |
IgG, % (n) | 63.3 (19) | 40.0 (12) | 0 (0) |
IgM/IgG, % (n) | 32.1 (9) | 3.3 (1) | 0 (0) |
